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MECHANISTIC INSIGHTS INTO VANCOMYCIN NON-SUSCEPTIBILITY 
IN CLOSTRIDIOIDES DIFFICILE 
 
Ayesha Mahmood, B. S. 
 
Advisor: Charles Darkoh, Ph.D. 
 
C. difficile is a nosocomial, opportunistic pathogen that has become more 
hypervirulent over the last decade. Vancomycin is currently a frontline antibiotic for 
the treatment of C. difficile infections. Yet, strains of C. difficile are becoming non-
susceptible to vancomycin. Emergence of the vancomycin non-susceptible phenotype 
has led to various questions including: What resistance elements are present that 
might contribute to the phenotype? Are these elements located on the chromosome 
or a plasmid? Where did these elements originate from?  To address these questions, 
whole genome sequence analysis was performed to survey genes that may be 
involved in the vancomycin non-susceptible phenotype. Bioinformatic analysis was 
used to answer whether putative vancomycin-resistance genes were chromosomal or 
plasmid based. Culture-dependent methods were used to detect enterococci from 
stools of patients from Texas and Kenya infected with C. difficile and this was 
supplemented with patient data to describe co-colonization in the gut and its effects 
on patients.  
The sequencing analysis revealed the presence of a putative van gene cluster 
in all isolates tested. The presence of vancomycin-resistance elements varied among 
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the isolates and included: vanRS, vanW, vanH, and vanZ. In silico analysis of 
sequences suggested that the putative vancomycin-resistance genes were 
chromosomal. A high prevalence of enterococci and vancomycin-resistant 
enterococci (VRE) was observed in the stools of C. difficile patients from both Kenya 
and Texas. In addition, the presence of enterococci increased the duration of CDI 
symptoms and this might also promote selection of non-spore forming C. difficile 
isolates. Finally, high proportions of VRE and non-susceptible C. difficile isolates were 
found in the same stools, suggesting a potential source of resistance elements. 
Although rigorous functional analysis is needed to confirm the specific genes 
responsible for vancomycin non-susceptibility in C. difficile, the presence of 
vancomycin-resistance genes underlines a promising avenue for further 
experimentation. Knowing that the genes are likely chromosomal will help in 
downstream characterization of these genes. Given the correlation between 
vancomycin-resistant enterococci and the vancomycin non-susceptibility phenotype 
in C. difficile, and the shared epidemiology between the two bacteria, it is plausible 
that these resistance elements may have originated from Enterococci spp, however, 
further genetic analysis is needed to confirm this observation. Overall, this study has 
shed some light on the mechanism of vancomycin non-susceptibility in C. difficile and 
has highlighted avenues for further exploration. Moreover, the relationship between 
Enterococci spp. and C. difficile during infection has become clearer and might 
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 C. difficile characteristics and epidemiology 
 
C. difficile was first isolated and described from the stools of infants in 1935 (1). 
These novel bacteria were characterized as obligate anaerobic, “heavy-bodied rods” 
containing spores (1). Additionally, it was determined that bacterial cultures and 
toxigenic supernatant could cause severe disease in guinea pigs, indicating 
pathogenicity of the newfound bacterium (1). Based on the physical properties and 
difficult cultivation processes, this unknown pathogen was named Bacillus difficilis. 
Now, this Gram-positive bacterium has been reclassified as Clostridioides 
(Clostridium) difficile (2). Over time, C. difficile infection (CDI) became associated with 
gastrointestinal disease initiated from antibiotic use (3, 4), and today, it is the number 
one cause of antibiotic associated diarrhea and an important nosocomial pathogen (5-
7). C. difficile can be an asymptomatic colonizer in about 0-15% of healthy adults (8). 
In neonates, the prevalence is more varied but can be substantial (18-90%) (7-15). 
One of the biggest risk-factors for the development of CDI is broad-spectrum 
antibiotic use, as this diminishes colonization resistance by gut commensals and 
provides an ideal environment for C. difficile overgrowth (16-18). Moreover, the use of 
proton-pump inhibitors can contribute to CDI development (19). Immunocompromised 
patients, individuals with underlying conditions, or individuals of advanced age may 
also be more susceptible to CDI (16, 20). 
 Over the past 20 years, the emergence of hypervirulent strains have made the 
treatment and control of CDI even more difficult (3). Hypervirulent strains sporulate 
earlier, thus aiding in recurrence of disease since the spores are not affected by 
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antibiotics (3, 21). This is complicated further with antibiotic resistance seen in 
hypervirulent strains. Clinical C. difficile ribotype (RT) 027 has shown resistance to 
erythromycin, fluoroquinolones, and ciprofloxacin, in addition to second-generation 
cephalosporins, and to a lesser extent, third-generation cephalosporins (3). Also, 
multiple β-lactamases can be encoded in C. difficile, which contributes to β-lactamase 
resistance (3). Genes associated with conferring macrolide resistance have also been 
found in C. difficile (3). RT 027 was first described in Canada, but has quickly become 
the dominant strain worldwide and is endemic to the U.S. (3). Another hypervirulent 
strain, RT 078, has exhibited similar levels of infection severity throughout Europe (3), 
while RT 001, RT 017, and RT 018 have shown clindamycin resistance (19). 
 In addition to emergence of hypervirulent strains, the changing epidemiology 
of CDI has expanded to include groups not classically regarded as at-risk for C. difficile 
infection including children, pregnant woman, and individuals with no previous 
healthcare contact (5, 7, 22). The treatment costs of CDI in the United states is 
estimated to be $1.3-7 billion annually (7, 23-25). The growing severity and burden of 
this pathogen necessitates further examination of its pathogenesis and epidemiology.  
 
 C. difficile pathogenesis 
 
 
Disruption of the commensal gut microbiota is a key determinant in C. difficile 
colonization. This commonly occurs through the use of broad-spectrum antibiotics or 
proton pump inhibitors (16-19). Commensal gut microorganisms metabolize short 
chain fatty acids and free sialic acid in the gut, however, when these bacteria are 
depleted, C. difficile is able to utilize the abundant metabolites and grow unchecked 
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(26). Furthermore, bacteriocin production by some commensals can limit C. difficile 
overgrowth (26-28). The lack of interactions with competing bacteria and abundance 
of growth resources, space, and nutrients, lay the groundwork for CDI development 
(26). 
 The pathogenesis of C. difficile, including genetic variation among isolates, and 
host immune responses lead to a spectrum of disease states (18). Presentation 
includes asymptomatic carriage, diarrhea, pseudomembranous colitis, and toxin 
megacolon. In some cases, these symptoms culminate in death (18). As an obligate 
anaerobe, C. difficile produces spores to survive in normally toxic aerobic 
environment. These spores are transferred between surfaces via other individuals and 
can eventually be ingested. The spore coat allows for C. difficile survival in the acidic 
gastric environment, and upon entry into the small intestines, bile acids induce 
transformation of spores into vegetative cells. When combined with reduced 
colonization resistance in the gut from broad-spectrum antibiotic use, these vegetative 
cells can proliferate and begin their virulence process. Once C. difficile bacteria have 
reached a critical density, they start producing their major virulence factors, toxins A 
and B. These toxins, encoded by TcdA and TcdB, respectively (18, 26) contain Rho 
and Rac glucosyl transferase domains (GTDs) that can glycosylate and inactivate Rho 
and Rac GTPases of colonic epithelial cells (26, 29). This leads to cytoskeleton 
deformation (actin polymerization) and cell rounding in target cells (20, 29). Moreover, 
the cytoskeletal restructure results in the degeneration of tight junctions between cells. 
Loss of epithelial barrier function leads to increased leakiness in the gut which results 
in diarrheal symptoms in the affected individual. Local C. difficile toxin production 
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promotes recruitment of immune factors such as tumor necrosis factor-α (TNF-α), 
interferon- γ (IFN-γ), and proinflammatory interleukins (ILs) (26, 30). This, in turn, 
exacerbates vascular permeability and recruitment of monocytes and neutrophils (30, 
31). Local production of hydrolytic enzymes by immune cells can induce connective 
tissue degradation and subsequent colitis in the patient (26). Accumulation of immune 
cells can also lead to pseudomembrane formation, another hallmark symptom of CDI 
(30). In certain cases, extracolonic manifestations can appear in the form of 
bacteremia, small bowel infection, and reactive arthritis (17, 32, 33).  
In the endogenous form of CDI, the individual is already colonized with C. difficile, 
which can overgrow with loss of colonization resistance. Although treatment with oral 
antibiotics has been the standard of care, it does not promote recolonization of normal 
gut flora, potentiating recurrent cases of CDI in about 15-30% of adult patients (34).  
 
 C. difficile treatment 
 
CDI treatment is focused around bacterial clearance and promotion of normal flora 
to prevent recurrence. Classification of CDI severity (i.e. first infection, recurrent 
infection, severe, etc.) also aids in intervention determination (3, 35). Previously, the 
first line of drug used for treatment was metronidazole (36-40), a nitroimidazole 
antibiotic that deforms and destabilizes the helical DNA structure, preventing protein 
synthesis, and eventually leads to bacterial death (41). It was previously thought that 
metronidazole treatment would limit the use of vancomycin and prevent downstream 
overgrowth of vancomycin-resistant enterococci (VRE) (36). However, recent studies 
have shown that metronidazole use can be associated with VRE and that VRE 
colonization seem to be at similar levels with either oral metronidazole or oral 
5	
	
vancomycin treatment (36, 42). Due to neurotoxicity from prolonged use, 
metronidazole is not ideal for long-term or recurrent cases of C. difficile (41). In 
addition, there have been increasing reports of its ineffectiveness in CDI cases (43-
45). Consequently, the Infectious Diseases Society of America (IDSA) and the Society 
for Healthcare Epidemiology of America (SEHA) recently recommended vancomycin, 
followed by fidaxomicin, as the drug of choice (36, 37, 46, 47).  
 Other first-line antibiotics are available for use but remain underutilized. 
Rifaximin can be applied for a first-time infection, as well as teicoplanin, however C. 
difficile isolates have shown resistance to rifaximin in about 30% of samples (48) while 
the latter is not approved for use in the U.S. (3, 7). More recently, one study by Alberto, 
et al. did not show any statistically significant differences in infection rates between a 
cohort of patients with advanced liver disease that were either treated or not treated 
with rifaximin (49). 
 The glycopeptide vancomycin has been used for the treatment of severe and 
recurrent cases of CDI effectively (37), but now it has become the major antibiotic of 
choice for treatment (50, 51).  
Fidaxomicin is a relatively newer antibiotic and has been shown to be effective 
for CDI treatment by inhibiting RNA synthesis, spore formation, and toxin production 
(33, 52-55). Unfortunately, it is quite costly for use as a first-line antibiotic, and 
combined with limited data on outcomes, prevents its widespread use (18, 56). Given 
its ability to reduce recurrence rates, it is a promising drug for CDI treatment, but 
requires a reduction of cost and more patient studies to be widely accepted.  
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 Fecal microbial transplants (FMTs) have also been a widely debated treatment 
option for CDI. Many studies have looked at the efficacy of FMTs, but their use has 
only been approved for recurrent cases of CDI (26). Although FMTs have shown 
success in up to 89% of patients (57), FMT usage has been met with hesitance due 
to perceived downstream side effects, such as reports of obesity and long-term health 
concerns (58). 
 Spore-formulation is a method similar to FMT, but is more selective of which 
microbial species are introduced into the infected individual. Spores of competitive 
bacterial strains can be introduced into the gut microenvironment, which has been 
successful in a few pilot studies (59, 60). In one case, spores of nontoxigenic C. 
difficile strains were introduced into patients with recurrent CDI and showed a 
decrease in recurrence when compared to the control group (59). However, the 
treatment group still exhibited a large percentage of adverse effects linked to 
treatment (59). In another example, firmicute spores from healthy donors were used 
as competitive remodeling of the gut microbiota, and the results showed a reduction 
in recurrence, however, the study itself had some limitations that questioned the 
validity of the study (60). This relatively new avenue of therapeutic intervention is 
promising but requires more studies to determine the efficacy of such a treatment. 
 An over the counter (OTC) treatment option to alleviate symptoms is the use of 
probiotics. Probiotics can be defined as microbes consumed for the purpose of 
conferring some sort of health benefit (61). Probiotics have three major modes of 
conferring advantage to the host including (1) immunomodulation, (2) providing 
colonization resistance by preventing other, potentially pathogenic bacteria from 
7	
	
adhering to intestinal epithelia and invading, and (3) interacting with harmful bacterial 
effectors, such as Saccharomyces boulardii providing protection against C. difficile 
toxin A (3, 61). Probiotics can be consumed through foods containing the beneficial 
microbes or through manufactured, lyophilized pills of the microbes (61). Probiotics 
have been shown to prevent recurrence in CDI patients (62, 63). Generally regarded 
as safe, there is an underlying concern of transfer of antibiotic resistance from the 
probiotic bacteria to resident gut bacteria. Concurrent probiotic and antibiotic use can 
promote a reservoir of antibiotic-resistance determinants (64, 65). 
 Bacteriocins are anti-microbial proteinaceous molecules produced by bacteria 
to target other bacteria. Three bacteriocins show the most activity against C. difficile. 
Lacticin 3147 is a two-component antibiotic produced by Lactobacillus lactis (66). Not 
only does Lacticin 3147 provides C. difficile growth reduction in various in vitro models 
(67). Thuricin CD, produced by Bacillus thuringiensis, has been shown to be potent 
against C. difficile (27, 68). Finally, Nisin is a polypeptide bacteriocin produced by 
Lactobacillus lactis. It has been shown to be as effective as vancomycin and inhibits 
growth of C. difficile post spore germination (69). These bacteriocins, and many 
others, may be effective against treatment of CDI. While Nisin is  generally recognized 
as safe, and can be used as food additive, lacticin and Thuricin CD do not survive 
gastric transit and must rely on administration via enema, which is not always the 
easiest treatment route for CDI patients (3).   
Other non-antibiotic treatments are also being actively explored, including 
small molecule inhibitors for TcdB receptors (70). Also, bis-cyclic guanidine 
compounds that mimic host defense proteins seem promising for CDI treatment (71). 
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Monoclonal antibodies against toxins A and B have been attempted in patients at high-
risk for recurrence and did show a lower rate of recurrence. However, when compared 
to vancomycin, antibody treatment showed a different microbial succession profile 
which could have unknown consequences (32, 72).  
There are a variety of treatments available for CDI, but pitfalls exist with each, 
especially with the relative novelty of some therapeutics and unknown consequences. 
Vancomycin is currently the most widely used drug for the treatment of CDI. 
 
 Gram-positive cell wall biogenesis 
 
In Gram-positive bacteria, the process of cell wall biogenesis begins with D-
alanine, formed by conversion of L-alanine via a racemization. Two molecules of D-
alanine are joined together by a Ddl ligase in the cytosol (73). A uracil dipeptide N-
acetylmuramyl-tripeptide (NAM), consisting of L-Ala, D-Glu, and L-Lys, is ligated to the 
D-Ala-D-ala forming a pentapeptide that is linked to an undecaprenol lipid carrier. Once 
this molecule is attached to N-acetyl glucosamine (NAG), the lipid carrier flips across 
the cell membrane (73). Transglycosylation activity by penicillin binding proteins 
(PBPs) aids in elongating nascent peptidoglycan while transpeptidation activity 





Figure 1: Gram-positive peptidoglycan structure is characterized by a N-
acetylglucosamine (NAG) and N-acetylmuramic acid (NAM) backbone and 
crosslinked pentapeptide chains (73, 74). The alternating NAG and NAM subunits 
are shown in purple hexagons. Each NAM subunit is attached to a pentapeptide chain 
composed of L-Ala, D-Gln, L-Lys, D-ala, and D-ala. A transpeptidase (brown) creates a 




1.5. Vancomycin mode of action 
 
Vancomycin works by preventing polymerization of the peptidoglycan cell wall. 
During bacterial cell wall biogenesis, vancomycin binds to the terminal D-alanyl-D-
alanine moiety, sterically hindering penicillin binding proteins (PBPs) from enzymatic 
cross-linking of peptidoglycan precursors. This creates disruption of the cell wall and 





Figure 2: Vancomycin prevents peptidoglycan elongation (76, 77). Vancomycin 
binds to the terminal D-Ala-D-ala peptides, sterically hindering penicillin binding 
proteins (PBPs) from performing transpeptidation activities. The peptidoglycan 






 Vancomycin resistance 
 
As described earlier, vancomycin works by binding to the terminal D-alanyl-D-
alanine amino acids of the pentapeptide chain. To combat this, some bacteria can 
convert their terminal residues to alternative precursors, including D-alanine-D-lactate 
and D-alanine-D-serine (Figure 3). Most commonly, high level vancomycin-resistance 
phenotypes have terminal endings of D-ala-D-lactate, which lowers the binding affinity 
of vancomycin up to 1000-fold (78). 
Vancomycin resistance in certain species of bacteria (e.g. enterococcus) is 
encoded on a van operon (78), although alternatives exist. For example, Gram-
negative bacteria are intrinsically resistant to glycopeptides given the impenetrable 
outer membrane, non-conductive to the passage of glycopeptides (79). There are 
various phenotypes associated with glycopeptide resistance and are differentiated 
based on resistance characteristics. The van operon usually contains a regulatory 
region carrying the vanR and vanS genes. VanRS is a two-component sensor-
response regulator system that functions by detecting disruptions in the cell wall 
and/or by sensing vancomycin (78, 80). The essential components of some operons 
include vanH, vanT, a van ligase, and vanX. VanH encodes a D-hydroxyacid 
dehydrogenase responsible for reducing free pyruvate in the cell into D-lactate; this 
gene is found with bacteria producing D-ala-D-lactate precursors (73). VanT is usually 





Figure 3: Bacteria may respond to vancomycin by altering terminal peptides 
(77). Some bacteria may replace the terminal residues of the pentapeptide chain to 
either a D-alanine-D-lactate or D-alanine-D-serine (not shown) to reduce vancomycin 
binding affinity, resulting in a resistance phenotype that allows normal 




In vanA-type resistance, the van ligases form an ester bond between D-D-
alanine and D-lactate (75). vanX is a D,D-dipeptidase responsible for increasing free 
D-alanine in the cell by cleaving the terminal peptide repeats (82). The accessory 
component of the operon includes vanY, a D,D carboxypeptidase that increases D-
alanine amounts by cleaving them directly from the cell membrane, and vanZ, which 
is only found in vanA carrying bacteria and confers resistance to teicoplanin (83).  
Besides Enterococcus spp., there has been an isolate of Bacillus circulans 
(VR0709) that contains a vanA-like, chromosomally encoded gene cluster (84). 
Although all genes in the vanA operon were present, genes for a transposase and 
resolvase  similar to some Enterococcus spp. were absent, and instead were replaced 
by an open reading frame with a low percentage (28%) homology to the vanA operon 
carried on Enterococcal Tn1546, yielding in a 9.2 kb fragment (84). Overall this study 
showed that vancomycin resistance in this case did not arise from an Enterococcus 
species member (84).  
Some isolates of Staphylococcus aureus have also demonstrated vancomycin 
resistance. Due to an increase of methicillin-resistant S. aureus (MRSA), the antibiotic 
of choice for treatment has been vancomycin (85). Initially, decreased susceptibility to 
vancomycin was described in a MRSA isolate from Japan (86). Given the low levels 
of vancomycin resistance (MIC = 3-8 µg/ml), this, and other isolates with similar MIC 
phenotypes were called vancomycin intermediate Staphylococcus aureus (VISA) (85). 
It was shown that these isolates did not gain resistance from an extrachromosomal 
element, but rather from mutations in two-component systems regulating transcription 
of cell wall components that arose during prolonged vancomycin treatments (85).  
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C. difficile has largely been regarded as susceptible to vancomycin, but some 
studies have indicated the presence of non-susceptible isolates (87). An initial study 
with a cohort of samples between 1983 and 2004 showed that about 6 out of 110 
samples showed non-susceptibilities between 2-4 µg/ml vancomycin (88). One study 
showed that 3 out of 38 samples were non-susceptible to vancomycin in Poland (89). 
Samples taken between 1993-2001 in Spain showed that 10% of samples were non-
susceptible up to 16 µg/ml vancomycin (90). In a 2013 study, Goudarzi et al. showed 
that 8% of their isolates (6/75)  were not susceptible to vancomycin up to 4 µg/ml (91). 
An Israeli study from 2014 indicated that about 8% of isolates were non-susceptible 
(92). Of these isolates, about 2% were of strain 027, which had the most instances of 
non-susceptibilities, whereas strain cr-02 had the highest degree of non-
susceptibilities (up to 6 µg/ml vancomycin) (92). A more recent European study 
showed that about 3% (n=918) of samples were non-susceptible up to 8 µg/ml with 
notable ribotypes including 014, 027, 078, 126, 001/072 (93). In another US Study 
from 2011, about 18% of isolates (n=925) were considered resistant according to 
EUCAST guidelines up to 4 µg/ml (94).  
 
1.6.1. Vancomycin-resistant phenotypes 
 
 Even though VanA is the most common vancomycin-resistance phenotype, 
there are many other variations that have been described in Enterococcus spp. 




Table 1: Features of glycopeptide resistances described in Enterococcus spp. 
(95-99). Resistance types are classified based on MIC, mode of transfer, genetic 
determinant (encoded on the chromosome [ch] or plasmid [p]), and mode of 
expression, either constitutive (C) or inducible (I). ND indicates not determined. 





VanA 64-1024 Acquired Ch or P I (75, 100-102) 
VanB 4-1024 Acquired Ch or P I (100, 103, 104) 
VanC 2-32 Intrinsic Ch C or I (100, 105, 106) 
VanD 64-128 Acquired Ch C or I (107) 
VanE 8-32 Acquired ND C or I (108, 109) 
VanG 16-32 Acquired ND C or I (110, 111) 
VanL 8 Acquired Ch I (112) 
VanM ND Acquired ND I (113) 





























Figure 4: Arrangements of vancomycin-resistance types described in 
Enterococcus spp. (78, 97, 115). Vancomycin-resistance operons described in 
Enterococcus spp. are classified based on the presence of either a (a) D-alanine-D-









Enterococci species are Gram-positive, opportunistic pathogens and  are classified as 
lactic acid bacteria  that produce bacteriocins (100). They are asymptomatic 
colonizers of the human gut, but can be found in other locations including the 
oropharynx, soft tissue wounds, and the perineal region (116). Major diseases caused 
by these pathogens include urinary tract infections (UTIs), endocarditis, and 
bacteremia, many in a nosocomial fashion (116). Enterococcus faecium and E. 
faecalis are responsible for most of these infections. However, E. gallinarum, E. 
casseliflavus, E. durans, E. avium, and E. raffinosis have been reported to cause up 
to 5% of Enterococcal infections (83, 117, 118). Similar to CDI, enterococcal infections 
can be initiated by prior broad-spectrum antibiotic use, such as cephalosporins, 
fluoroquinolones, and macrolides (78, 119).  
The usual treatment for enterococcal infections includes a combination of 
penicillin and ampicillin, or vancomycin in conjunction with an aminoglycoside (117). 
Alarmingly, multi-drug resistant strains of enterococci have been emerging since the 
1980’s, which has made them more difficult to treat (120-123). In human feces, 
enterococci may represent up to 1% of the indigenous microflora (120, 124-126). In 
children, one study of infants in the intensive care unit indicates a percentage of 23% 
of enterococcal colonization, with 57% of those being multidrug resistant (127). In a 
cohort of healthy adults from Laos, 73% were colonized with Enterococci spp (125). 
Of those, about 45% were found to be E. faecalis, and 55% were E. faecium, as 
determined by biochemical and physical characteristics (125). Further examination of 
the two Enterococci species showed a vancomycin resistance rate of 13.8% among 
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volunteers (125). Other estimates of VRE in the United States indicate prevalences of 
about 30%, with 77% caused by E. faecium, and 9% by E. faecalis (78). There are 
other species that can be implicated in VRE infections, including E. gallinarum, E. 
caseliflavus, E. avium and E. raffinosus (78). VRE prevalence can increase to 99% in 
hospital patients (120, 128) . 
 
1.7.1. Vancomycin-resistant enterococci 
 
Vancomycin resistance has been documented in Enterococcus since the 
1980’s (42). Two species are of primary importance, E. faecalis and E. faecium, as 
they cause severe infections, sometimes associated with multi-drug resistance. 
Enterococcus can be intrinsically resistant to β-lactam antibiotics and can acquire 
resistance to other antibiotic types such as glycopeptides (78). Glycopeptide 
resistance in enterococci is acquired via transposons or other genetic elements 
carrying the appropriate genes. These elements can be found as plasmids or can 
become integrated chromosomally (78). In one case, it was posited that two distinct 
vanA type elements could be carried by certain isolates that localize both to the 
chromosome and a conjugative plasmid (129). 
 Vancomycin resistance can be encoded in multiple ways. E. faecalis (V583) 
encodes resistance on mobile element EF1955-EF1963, which shares sequence 
homology with vanB type genes found on Tn1549, but differs significantly in the 







 C. difficile and enterococci co-colonization of the colon 
 
C. difficile and VRE are commonly found co-colonized in stools. Proliferation and 
subsequent disease development of both bacteria is dependent on similar risk factors, 
such as treatment with fluoroquinolones (78, 131). Patients who are 
immunocompromised, have underlying health conditions, or are of advanced age may 
also be more susceptible to both pathogens (132, 133). Treatment of CDI by 
vancomycin is also a risk factor for VRE development (119, 131). In pediatric settings 
(1 month to 18 years old), one study shows a VRE colonization rate of 18.6% among 
pediatric intensive care unit  patients (134). Another study reports 63.3% VRE 
colonization in hospitalized children (135). Surveillance studies from 1994 to 2018 
indicated a VRE-C. difficile co-colonization rate between 3.2- 55% in adult patients 
(119, 136-145). Some common characteristics associated with co-colonization include 
a higher percentage of VRE colonization in stools containing toxin-producing C. 
difficile isolates (119, 140). Leber et al. (2001) showed a 3.2% VRE colonization in 
patients with toxigenic C. difficile, with an odds ratio of 2.3 times that of VRE co-
colonization with non-toxigenic C. difficile (141). Other reports are as high as 17% 
(140) and 21% VRE colonization in toxigenic C. difficile (142). One study even 
describes CDI patients having 55.7% colonization with VRE (145).  
 C. difficile and Enterococcus spp. have become two of the most prevalent 
agents of hospital-acquired infections. Given the emergence and increase of C. 
difficile hypervirulent strains and the rise in multidrug-resistant enterococci, 





  Genetic transfer between gut microbiota 
 
C. difficile has a highly plastic, mosaic genome, with up to 11% of its whole genome 
(~473 kbp) consisting of mobile genetic elements [MGE]  (146-148). The Clostridia 
genus displays examples of insertion sequences, conjugative and non-conjugative 
transposons, phages, and plasmids that may aid in genetic transfer of resistance 
elements, but at the forefront remains integrative conjugative elements  (146, 148). 
Genetic transfer of antibiotic resistance encoded by these genetic elements have been 
well-documented between Clostridia and other firmicutes (148). Transposon 5397 
carries tetracycline resistance genes and was shown to be transferred from C. difficile 
to E. faecalis JH2-2 in vitro (149). Additionally, the same study described the transfer 
from E. faecalis transconjugant EF20 to a C. difficile isolate belonging to the 027 
ribotype, which is considered endemic (149).  
  Enterococcus faecalis Tn916 encodes tetracycline resistance via the tet (M) 
determinant (146), and belongs to a family of conjugative transposons that also 
contains the Streptococcus pneumoniae Tn1545, which encodes erythromycin 
resistance via erm(AM) (146). This family of Tn916-like/Tn1545-like transposons have 
been described in multiple bacteria including C. difficile. Tn5397, one of these Tn916-
like elements, has been shown to share homology with tetracycline encoding regions 
of Tn916 in C. difficile (146). Another study has observed the transfer of Tn916 from 
C. difficile 630 to B. subtilis and vice versa. 
 In C. difficile, resistance to the macrolide-lincosamide-streptogramin B group of 
antibiotics conferred by the erm(B) genes is contained on the conjugative transposon 
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Tn6194 (150). Transfer of this element was shown to occur with C. difficile 
conspecifics and with E. faecalis (150). Another study showed transfer from C. difficile 
to Staphylococcus aureus (151). These studies indicate the propensity of conjugative 
transfer between enterococcus and C. difficile.  
C. difficile itself does not have many plasmids characterized and most are cryptic 
or do not contribute to a virulence phenotype (146, 152). To date, two plasmids have 
been characterized in C. difficile: pCD630 (7.8 kb) and pCD6 (6.8 kb) (147, 153). Also, 
in a study identifying and characterizing plasmids from C. difficile, only 15 of the 82 
samples showed presence of plasmids (ranging in size from 4.5 to 75 kb) and did not 
correlate to any resistance genes (154). Some work has been done to show plasmid 
transfer from one bacterium to C. difficile, but this was done artificially to increase 
genetic tractability of C. difficile (153, 155). Overall, these studies require 
supplementation with newer ones given the genetic plasticity of C. difficile and the rise 
of antibiotic resistance in general.  
Whether contained on a plasmid or other MGE, C. difficile has shown an ability for 
horizontal gene transfer (HGT) not only between conspecifics but also with other 
bacterial species. Given the rise of antibiotic resistance in other bacteria residing in 
the gut, C. difficile is poised to acquire new types of antibiotic resistance given the 
proper selection pressure.  
 
 Other vancomycin-resistant bacteria in the gut 
 
In order to fully appreciate antibiotic resistance present in the gut microbiome, it is 
necessary to discuss other bacterial species that exhibit vancomycin resistance as 
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these may play a role in the emergence of vancomycin-resistant C. difficile. So far, 
major consideration has been given to enterococcus as they have a well-documented 
history of vancomycin resistance and they occupy the same niche as C. difficile. 
Another potential source of vancomycin resistance could be Staphylococcus aureus.  
Although not necessarily a part of the gut microbiome during CDI, probiotics have 
been used increasingly as therapeutics for diarrheal symptoms. These microbes could 
be another reservoir given their rise in popularity for recolonizing the normal gut 
microbiota. Lactobacillus casei group (LCG), composed of L. casei, L. paracasei, and 
L. rhamnosus. are common probiotic bacteria (156). They are Gram-positive, rod-
shaped, non-spore forming, and non-motile  that colonize the gastrointestinal and 
urogenital tracts (156). These bacteria are also commonly found in various foods 
(156). It has been known for a while that vancomycin-resistance has been circulating 
in the Lactobacillus population. In one study, it was shown that 100% of lactobacillus 
strains tested were resistant to vancomycin (157). Other studies have shown that 
exposure to probiotic bacteria is a significant risk-factor for vancomycin-resistant 
enterococci colonization in neonates (158) 
Weisella spp. were first recognized in 1993 (159). They share many properties with 
C. difficile bacteria (i.e. short rods/coccobacilli, Gram-positive, etc.) but are unique in 
that they are non-spore forming and are intrinsically resistant to vancomycin (159). 
They are commonly confused for members of the genus Lactobacillus and are 
disregarded as contaminants in clinical samples (159). Weisella inhabits many foods 
and can be a part of the normal human flora; it has also been recovered from the stool 
of many healthy individuals (159, 160). A review by Kamboj, et al. describes how W. 
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confusa can cause cases of bacteremia, so it is a relevant human pathogen. 
Vancomycin resistance has also been described in these bacteria (161, 162). Taken 
together, these bacteria pose as alternative reservoirs of vancomycin-resistant 
elements. 
 
 Evaluation of vancomycin non-susceptibility in C. difficile  
 
Analysis of C. difficile-positive stool samples from Texas for vancomycin non-
susceptibility showed that 29% (n = 274) of the Texas samples were not susceptible 
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Figure 5: CDI-infected stools from Texas contain vancomycin non-susceptible 
C. difficile. CDI patient stools from Texas were screened for non-susceptibility to 
vancomycin on C. difficile selective plates containing 4 µg/ml vancomycin.  
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So far, no clear mechanism exists for vancomycin resistance in C. difficile. The 
literature has described the presence of a vanG cluster originating from E. faecalis in 
many clinical isolates of C. difficile. The inducibility and functionality of these genes 
have not been confirmed and they are not recognized as promoting a vancomycin 
non-susceptibility phenotype, as there are minimal changes in MICs and an absence 
of modified peptidoglycan precursors (110, 163, 164).  
Knowledge of the mechanism may provide therapeutic targets with long-term 
significance for clinical treatment and public health. Many intestinal gut bacteria such 
as Enterococcus and Staphylococcus species encode vancomycin resistance on the 
plasmid Tn1546. However, it is not known whether the vancomycin non-susceptibility 
observed in C. difficile isolates is conferred by genes located in the chromosome or 
on a plasmid. The overall goal of this project is to demonstrate the source of 
vancomycin resistance in clinical C. difficile isolates. Analysis of whole-genome C. 
difficile sequences available on NCBI demonstrated a lack of vancomycin-resistance 
associated genes in the genomes of sequenced strains, except the vanG homologs 
described above. This led to the hypothesis that the vancomycin resistance observed 
in the C. difficile isolates may be transferred from other co-inhabiting gut bacteria, 
such as Enterococcus species and may be plasmid mediated. Two aims were 
designed to address the hypothesis, and these are: 
 Specific Aim 1: To survey vancomycin-resistance genes in the C. difficile 
genome and isolate and characterize plasmids from vancomycin-resistant 
clinical C. difficile isolates. The goal of this aim was to determine what vancomycin-
resistance genes were present that may contribute to the resistance phenotype and 
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to describe if putative vancomycin resistance genes in C. difficile are plasmid 
mediated or chromosomally encoded. Whole genome sequencing, along with 
comprehensive in silico analysis were employed to address this aim.  
Specific Aim 2: To estimate the prevalence of Enterococcus spp. in stools 
containing C. difficile and to test if vancomycin-resistance may have originated 
from Enterococcus species. Patients with C. difficile stools were investigated for co-
colonization with enterococcus, and vancomycin-resistance transfer between the two 
bacteria was investigated. CDI stool samples were screened for the presence of (1) 
enterococcus and (2) vancomycin-resistant enterococcus. An epidemiological 
approach was used to characterize CDI infection in terms of enterococcus co-
colonization. Finally, vancomycin-susceptible C. difficile isolates were co-cultured with 
enterococci to determine if vancomycin-resistance can be transferred to the C. difficile 
isolates.  
 
2. Materials and Methods 
 
 Stool sample collection 
 
Clinical stool samples were obtained from inpatients presenting with diarrhea at 
St. Luke’s Episcopal Hospital in Houston, TX from 2012-2018. Additional samples 
were collected from Kenyatta National Hospital in Nairobi, Kenya, and Kisii Teaching 
& Referral Hospital in Kisii, Kenya from 2016-2018. This study was approved by the 
Institutional Review Board (IRB) of The University of Texas Health Science Center at 
Houston and the Ethics Review Board of Kenyatta National Hospital and University of 
Nairobi (KNH/UoN-ERC). In Houston, patients identified to be positive for C. difficile 
toxin by the hospital’s laboratory were consecutively enrolled. All the stool samples 
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were initially tested by real-time PCR for the toxin genes and classified as C. difficile 
positive by the Medical Microbiology Laboratory at the hospital. In Nairobi, adult 
patients that reported to the two hospitals with diarrhea were sequentially enrolled and 
stool samples were collected for analysis. Stool samples were also obtained from 
children 5 years or younger presenting with diarrhea and gastroenteritis at Kenyatta 
National Hospital (Nairobi County, Kenya) from 2015 to 2018. All children presenting 
with diarrhea during the study period were sequentially enrolled in the study. The IRB 
approval stipulated that all the stool samples be de-identified so no patient information 
could be included in the current study. 
 
 Isolating vancomycin non-susceptible C. difficile from stool  
 
Each patient stool sample was spread on CDPA medium using a sterilized loop 
and incubated anaerobically at 37 oC for 48 h (165, 166). The C. difficile culture 
medium (CDPA) contains brain heart infusion (BHI) broth (Becton Dickinson, 
Cockeysville, MD) (37 g/l), agar (14 g/l), defibrinated horse blood (7%) (Quad Five, 
Ryegate, Montana), 150 µg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
(Zymo Research, Irvine, CA), p-cresol (0.025%), 0.1% sodium taurocholate (Sigma-
Aldrich, St. Louis, MO), D-cycloserine (500 µg/ml), and cefoxitin (16 µg/ml) (Fisher 
Scientific, Hampton, NH). Anaerobic conditions were maintained with an atmosphere 
of 10% H2, 5% CO2, and 85% N2 in a Bactron 600 anaerobic chamber (Sheldon 
Manufacturing, Inc, Cornelius, OR). To identify stool samples containing non-
susceptible C. difficile isolates, the stools were plated on CDPA only, and  CDPA 
containing 4 µg/ml vancomycin based on CLSI and EUCAST guidelines (167, 168). 
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The presence of C. difficile in the stools was confirmed using toxigenic C. difficile 
culture and PCR (169-172). Isolates confirmed as C. difficile positive and that 
demonstrated the vancomycin non-susceptible phenotype were saved as freezer 
stocks at -80 oC. 
 
 Determining minimum inhibitory concentration (MIC) 
 
To test the minimum inhibitory concentrations for the C. difficile vancomycin non-
susceptible isolates, the broth microdilution method was used (173, 174). Overnight 
C. difficile cultures inoculated from freezer stocks were used to inoculate 96-well 
plates. MICs for the  wild type control and clinical isolates were done using both 
Müeller-Hinton broth and brain-heart infusion (BHI) broth, a complex growth media 
commonly used for culturing C. difficile (175). 
 
 DNA Isolation and purification 
Freezer stocks were streaked onto CDPA containing 4 µg/ml vancomycin and 
incubated for 48 h anaerobically at 37 oC. Isolates were then cultured anaerobically at 
37 oC in BHI broth containing 4 µg/ml vancomycin overnight. Cultures were pelleted 
at 4000 rpm for 15 minutes at 4 oC.  DNA was isolated and purified using the Qiagen 
DNeasy Kit, according to the manufacturer’s instructions. DNA concentrations and 






 DNA sequencing and in silico genome analysis 
To assess whether the vancomycin non-susceptible C. difficile isolates harbored 
vancomycin-resistance elements, whole-genome sequencing was performed at the 
Genomics & Bioinformatics Service (Texas A&M University) on Illumina MiSeq 
Platform with paired-end reads. This analysis was performed on six of the non-
susceptible isolates with MICs ranging from 4 µg/ml to 64 µg/ml. These isolates were 
CD6 (4 µg/ml), TMC109 V (16 µg/ml), TMC544V2 (32 µg/ml), TMC579 (32 µg/ml), 
TMC 68V1B (64 µg/ml), and TMC024S (64 µg/ml). 
For the analysis, the  adapters were first removed by Trimmomatic (Version 0.39) 
(176) and reads were examined for quality with FastQC (Version 0.11.9) (177). 
SPAdes (version 3.14.0) was used to create  de novo assemblies for the clinical 
isolates (178).  
Assembly quality was evaluated in several ways. Initially, QUAST was used to 
determine quality as well as GC content (179). This report also provided information 
including the total length, N(50), and N(75) values. QUAST was utilized through the 
Patric web service (version 3.6.5) (180). The number of reads generated by Illumina 
sequencing was calculated by counting the number of lines present in the respective 
fastq files through a command line prompt and dividing that number by 4, to account 
for the three lines of descriptive data for each read. Coverage was determined in terms 
of depth and breadth. Empirical coverage depth was calculated using the following 
equation and an average read length of 290 bp for CD 6 isolate and 150 bp for all 










Coverage breadth is denoted as average percent total coverage; contigs were ordered 
using various C. difficile assemblies available from NCBI (Table 2) (181). Progressive 
Mauve alignment was used to align contigs (182-184) and a score assembly was used 
to assess the percent of bases missed with each alignment. An average of 
percentages was determined to give the final value.  
 
Table 2: Reference genomes from NCBI used to determine coverage for C. 
difficile clinical isolates. 
Strain Size GC content Refseq Reference 
020711 4.17 28.70 NZ_CP028530.1 (185) 
AK 4.32 28.72 NZ_CP027014.1 (186) 
ATCC43255 4.21 28.55 NZ_CM000604.1 (187) 
BR81 4.12 28.70 NZ_CP019870.1 (188) 
CBA7204 4.04 28.50 NZ_CP029566.1 (189) 
CD-17-01474 4.30 28.90 NZ_CP026591.1 (190) 
DH/NAP11/106/ST-42 4.09 28.60 NZ_CP022524.1 (191) 
FDAARGOS723 4.18 28.70 NZ_CP046327.1 (192) 
Mta-79 4.12 28.70 NZ_CP042267.1 (193) 





Assembled sequences were subjected to two different annotation processes. 
Primary annotations were done on the Rapid Annotation using Subsystem Technology 
(RAST) Server (Version 0.1.1) (195). RAST annotations were compared against 
secondary annotations made in Prokka (Version 2.1.1) (196).  
Annotation quality was determined via EvalIG which utilized the CheckM 
algorithm to determine completeness of sequence in comparison to a reference (197). 
Additionally, EvalCon was used to describe the coarse and fine consistency of the 
annotations (198); EvalIG and EvalCon were utilized through the Patric web service 
(version 3.6.5) (180). 
Regions of interests determined through annotation programs were searched 
through NCBI Open Reading Frame (ORF) Finder. Consensus annotations were 
manually assigned to genes using SnapGene Viewer (Version 5.0.7). To describe the 
evolutionary relationships between sequences, MEGA X (199) was used to construct 
a phylogenetic tree via the Neighbor-Joining method (200). Evolutionary distances 
were calculated based on the maximum composite likelihood method and are 
described in units of base substitutions per site (201). All ambiguous positions were 
removed for each sequence pair (pairwise deletions).  
BioEdit (Version 7.2.5) (202, 203) was as used to align C. difficile sequences 
based on the ClustalW algorithm and to construct sequence identity matrices (204).  
To determine if genes were located on the chromosome or on a plasmid, putative 
plasmid sequences were extracted from whole genome sequences using 
plasmidSPAdes (version 3.14.0) (205, 206). The resulting contigs were compared 
against sequences in the NCBI database via NCBI BLAST to determine if they 
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matched a plasmid or chromosomal DNA. Contig sequences less than 500 bp were 
excluded from the analysis. To validate the results, existing C. difficile plasmid 
sequences on NCBI (Table 3) were compared with extracted sequences from the 
plasmidSPAdes program (Table 3). Finally, both plasmid and chromosomal 
sequences were annotated with RAST to determine if vancomycin-resistance genes 




Table 3: Plasmid sequences from C. difficile deposited in the NCBI database. 
None of the plasmids contain vancomycin-resistance elements. NCBI has 18 
published plasmid sequences associated from C. difficile. No vancomycin-resistance 
elements were found in these plasmid sequences. 
 
  
Strain Plasmid RefSeq Size (kb) GC (%) CDS Van elements (Y/N) Ref. 
C. difficile strain pCD6 NC_005326.1 6.83 24.50 5 N (155) 
630 delta erm pCD630 NZ_CP016319.1 7.881 27.90 9 N (207) 
FDAARGOS_267 unnamed1 NZ_CP020425.2 45.187 28.13 64 N (208) 
FDAARGOS_267 unnamed2 NZ_CP020426.2 131.326 26.43 151 N (208) 
AK pAK1 NZ_CP027015.1 142.753 26.62 159 N (186) 
AK pAK2 NZ_CP027016.1 56.372 28.30 74 N (209) 
CD161 unnamed1 NZ_CP029155.1 130.529 26.23 151 N (210) 
CD161 unnamed2 NZ_CP029156.1 48.594 28.53 68 N (210) 
CDT4 unnamed1 NZ_CP029153.1 48.594 28.53 68 N (211) 
12038 unnamed1 NZ_CP033215.1 10.52 37.21 3 N (212) 
CD21062 unnamed1 NZ_CP033217.1 109.346 33.30 80 N (212) 
TW11 p_TW11 NZ_CP045225.1 42.254 25.08 43 N (213) 
TW11-RT078 p1 CP035500.1 42.254 25.08 43 N (214) 
630 pCD630 NC_008226.2 7.881 27.90 10 N (215) 
ATCC9689 = DSM1296 unnamed NZ_CP011969.1 45.187 28.13 64 N (216) 
BI1 pCDBI1 FN668942.1 45.258 28.03 0 N (217) 
BI1 unnamed FN668943.1 300.869 25.00 0 N (217) 
ERR022513 pCD-WTSI2 NZ_MG019960.1 12.526 26.55 15 N (218) 
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 Estimating prevalence of enterococci in CDI patients 
To detect presence of vancomycin-sensitive and vancomycin-resistant 
enterococci, patient stool samples were streaked onto Slanetz-Bartley Media 
(SBM)(Oxoid) (219). A loop-full of stool was streaked onto the medium containing 
either no vancomycin or  4 µg/ml vancomycin based on EUCAST breakpoints (168). 
The plates were incubated aerobically for 48 h at 37 ºC. Any consistent, non-
contaminating growth on SBM was considered positive for enterococci. The entire 
bacteria growth on the plate was pooled and inoculated into 4 ml of BHI broth. The 
culture was allowed to grow overnight at 37 °C. Stocks were saved by combining 900 
µl of culture with 100 µl of dimethyl sulfoxide (DMSO) (Fisher Scientific) in a 
microcentrifuge tube. The tubes were vortexed for a few seconds and stored at -80 
°C. Samples that did not grow were re-plated with the same procedure to confirm 
results.   
 
 Evaluating genetic transfer between enterococci and C. difficile 
Freezer stocks of select vancomycin-resistant enterococci were streaked onto (1) 
SBM plates to isolate single colonies, (2) SBM containing vancomycin to confirm the 
resistance phenotype, and (3) CDPA plates to ensure the samples would not grow on 
the C. difficile selective plates. C. difficile isolates demonstrating a vancomycin 
susceptible phenotype were streaked onto (1) CDPA plates to isolate single colonies, 
(2) CDPA with vancomycin to confirm the susceptibility phenotype, and (3) SBM plates 
to ensure C. difficile samples did not grow on the enterococcus selective media. Plates 
were incubated anaerobically at 37 °C for 48 h. Then, single colonies of both bacteria 
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were inoculated into 4 ml of BHI broth and incubated anaerobically overnight at 37 °C. 
The next day 500 µl of the enterococci culture and 500 µl of the C. difficile culture were 
combined into a 15 ml conical tube containing 3 ml of fresh BHI. Control tubes were 
also made by transferring either 1 ml of C. difficile culture into 3 ml of BHI or 1 ml of 
enterococcal culture into 3 ml BHI. All tubes were incubated anaerobically overnight 
at 37 °C. The following day, 200 µl each of overnight culture was deposited onto SBM, 
CDPA, and CDPA + 4 µg/ml vancomycin for the mixed culture, CDPA, CDPA + 
vancomycin, and SBM for the C. difficile control, and CDPA and SBM for the 
enterococcus control. These plates were incubated for 24 h anaerobically at 37 °C 
and observed for growth/no growth. Additionally, 1 ml overnight culture of each sample 
was transferred into 3 ml of fresh BHI. Propagation of culture and plating continued 
for 10 days.  
 
 Determining toxin production of C. difficile isolates 
 
Toxin activity was done using the Cdifftox activity assay as described previously 
(165, 169-171, 220, 221). Briefly, supernatant recovered from 48 hour C. difficile 
culture was combined with 30 µl of 30 mM p-nitrophenyl-β-D-glucopyranoside (Sigma-
Aldrich) in a sterile 96-well plate. Absorbance was measured at 410 nm after 
incubation at 37 °C for 24 h. The C. difficile TOX A/B II ELISA test (TechLab, 
Blacksburg, VA) was used for toxin production by testing 200 µl of the culture 





 Determining spore production of C. difficile isolates 
Freezer stocks were streaked on CDPA with 250 µg/ml D-cycloserine and 8 µg/ml 
cefoxitin and incubated for 48 hours. Single colonies were selected from the plates, 
inoculated in 4 ml BHI broth, and incubated for 5 days anaerobically. Following the 
incubation period, 1 ml of culture was transferred into a microcentrifuge tube and 
incubated at 65 ºC in a hot water bath for 30 minutes. Then, 200 µl of heat-shocked 
culture was streaked onto CDPA containing 0.1% sodium taurocholate and incubated 
for 48 hours anaerobically. Colony growth on the plate indicated presence of spores. 
 
 Statistical analysis 
Statistical analysis was performed using RStudio (version 1.2.1335) with the 
Epitools Package (222, 223). Pearson’s Chi-Squared Test for Independence with 
Yate’s Continuity Correction was used to determine if proportions between 
vancomycin-resistant Enterococcus and vancomycin-resistant C. difficile were 
significant, if co-colonization proportions affected chronic CDI symptoms, and if type 
of antibiotic used affected chronic CDI symptoms. A p-value of less than 0.05 was 
considered significant. Odds ratios and confidence intervals were calculated for 
prevalence of enterococci in C. difficile stools, prevalence of vancomycin-resistant 
enterococci in C. difficile stools, and presence of C. difficile spores in C. difficile-only 









  C. difficile genomes reveal presence of vancomycin-resistance 
elements 
Multiple de novo assemblies of the vancomycin non-susceptible C. difficile isolates 
yielded assembled genomes ranging from 4.07 to 4.26 Mbp, with relatively high N(50) 
and N(75) values (Table 4). N(50) and N(75) values describe the minimum length (bp) 
of either 50% or 75% of contigs, respectively. 
The assemblies for each isolate were broken down into contig size and coverage 
(Table 14-Table 19, Appendix A). For CD6, 2,178,790 paired reads produced 41 
contigs above 300 bp with a mean length of 99,156 and 24 contigs of ≥1,000 bp with 
a mean length of 169,032 bp (Table 14). For TMC109V, 4,456,654 paired reads 
produced 62 contigs above 300 bp with a mean length of 66,101 and 40 contigs of 
≥1,000 bp with a mean length of 102,183 bp (Table 15). For TMC544V2, 4,175,631 
paired reads produced 60 contigs above 300 bp with a mean length of 68,256 and 51 
contigs of ≥1,000 bp with a mean length of 80,211 bp (Table 16). For TMC579, 
4,449,583 paired reads produced 70 contigs above 300 bp with a mean length of 
58,147 and 57 contigs of ≥1,000 bp with a mean length of 71,301 bp (Table 17). For 
TMC68V1B, 4,184,738 paired reads produced 58 contigs above 300 bp with a mean 
length of 70,773 and 49 contigs of ≥1,000 bp with a mean length of 83,680 bp (Table 
18). Finally, for TMC024S, 4,313,776 paired reads produced 133 contigs above 300 
bp with a mean length of 38,152 and 71 contigs of ≥ 1,000 bp with a mean length of 





Table 4: Whole genome sequencing characteristics reflect quality assemblies 
of the sequences obtained from the C. difficile clinical isolates. Table values are 
based on assemblies produced by the SPAdes de novo assembly and QUAST 
pipelines.  















CD6 2,178,790 41 4,065,404 429,529 205,873 155X 92.5 28.44 
TMC109V 4,456,654 62 4,098,287 162,289 133,781 163X 93.7 28.42 
TMC544V2 4,175,631 60 4,095,333 140,966 81,329 153X 93.3 28.51 
TMC579 4,449,583 70 4,070,284 146,718 81,329 164X 92.9 28.50 
TMC68V1B 4,184,738 58 4,104,836 128,719 81,329 153X 93.5 28.49 





The annotated contigs revealed several vancomycin-resistance elements 
including a vancomycin resistance two-component system (VanRS) and a putative D-
alanine-(R)-lactate ligase (Table 5). Further analysis of the annotation data revealed a 





Table 5: Resistance elements found in C. difficile clinical isolates. Annotation by 
RAST via the PATRIC web server revealed the presence of vancomycin-resistance 




Mercury Resistance Operon 
Multidrug Resistance Efflux Pumps 
Cobalt-zinc-cadmium Resistance 
Multidrug Resistance, Gram-positive Bacteria 
Resistance to Vancomycin 











Evaluation of the annotation data  showed that the mapped genes were  reliable 
with relatively high coarse consistency values (>94%), while the fine consistency 
values span a range of values from 68.8% to 98.7% (Table 6). The EvalCon program 
uses a reference genome to determine which genes are expected and in what quantity 
(198). The coarse consistency indicates the percentage of expected genes that are 
present. Fine consistency indicates the number of genes that are present. A lower fine 
consistency would indicate a different number of genes than what was predicted 




Table 6: Annotation quality of the assemblies. Assemblies were submitted for 
annotation using RAST via the PATRIC web server, and EvalIG and EvalCon was 
used to determine the reliability of the annotations made by RAST.  





CD6 100 98.8 98.7 
TMC109V 100 95.6 80.9 
TMC579 100 97.8 93.6 
TMC544V2 100 98.3 95.3 
TMC68V1B 100 98.7 98.2 





The annotations were confirmed using NCBI BLAST and maps were created 
of regions showing any vancomycin-resistant elements. In the CD6 isolate, 
vancomycin resistant elements were found in 4 separate loci. (Note: the node/loci 
designation is arbitrary and used only for organizational purposes).  In node 1, locus 
2 there was a vanW ligase upstream of a D-alanyl-D-alanine carboxypeptidase; a 
second distinct vanW gene is present in node 4, locus 3. A vanZ gene associated with 
teicoplanin resistance and commonly found as part of the VanA operon is also found 
in the genome (node 4, locus 1). Finally, a vancomycin-resistance operon containing 
a putative van ligase (green) is present (node 1, locus 5). This operon contains other 
elements including vanRS and vanXY, but vanH, needed to form precursors 
terminating in lactate, is absent. Additionally, vanT, an alanine/serine racemase, is 








Figure 6: The C. difficile vancomycin non-susceptible isolate CD6 contains a 
putative vancomycin resistance operon and additional putative vancomycin 
resistance genes. Gene annotation software and sequence examination through 
NCBI BLAST revealed the location and identity of vancomycin-resistance elements 
including: D-alanyl-D-alanine carboxypeptidase (blue), putative van ligase (green), 







The TMC109V isolate has five copies of the vanZ gene (node 1, locus 1; node 2; node 
3; node 10, locus 2; and node 13) and two copies of vanW genes. The other 





Figure 7: The C. difficile vancomycin non-susceptible isolate TMC109V contains 
a putative vancomycin resistance operon and additional putative vancomycin 
resistance genes. Gene annotation software and sequence examination through 
NCBI BLAST revealed the location and identity of vancomycin-resistance elements 
including: D-alanyl-D-alanine carboxypeptidase (blue), putative van ligase (green), 




One feature in the TMC544V2 isolate is that the one instance of vanRS is flanked by 
a HAMP-domain containing protein and a hypothetical protein, while the other is found 
in the complete resistance operon in node 2. The sequences for both vanRS are not 
identical. Several vanZ genes (node 3, locus 1; node 3, locus 3; node 4, locus 2; node 
6) and vanW genes (node 3, locus 2; node 4, locus 1) are also present in the genome 







Figure 8: The C. difficile vancomycin non-susceptible isolate TMC544 V2 
contains a putative vancomycin resistance operon and additional putative 
vancomycin resistance genes. Gene annotation software and sequence 
examination through NCBI BLAST revealed the location and identity of vancomycin-
resistance elements including: D-alanyl-D-alanine carboxypeptidase (blue), putative 




The TMC579 isolate had elements almost identical to TMC544V2. The 
vancomycin resistance operon (node 1, locus 1) and the vanRS two-component 
system (node 2) are present, in addition to the same number of vanZ gene copies 
(node 1, locus 2; node 1, locus 4; node 3, locus 1; node 4) and vanW genes (node 1, 






Figure 9: The C. difficile vancomycin non-susceptible isolate TMC579 contains 
a putative vancomycin resistance operon and additional putative vancomycin 
resistance genes. Gene annotation software and sequence examination through 
NCBI BLAST revealed the location and identity of vancomycin-resistance elements 
including: D-alanyl-D-alanine carboxypeptidase (blue), putative van ligase (green), 
vanS (orange), vanR (red), vanW (dark green), and vanZ (pink).  
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The same trend is observed in the TMC68V1 B isolate with the resistance operon 
(node 2) and the vanRS two-component system (node 1) present. The vanZ genes 
copies (node 3, locus 1; node 3, locus 3; node 4, locus 2; node 6) and vanW genes 


















Figure 10: The C. difficile vancomycin non-susceptible isolate TMC68V1B 
contains a putative vancomycin resistance operon and additional putative 
vancomycin resistance genes. Gene annotation software and sequence 
examination through NCBI BLAST revealed the location and identity of vancomycin-
resistance elements including: D-alanyl-D-alanine carboxypeptidase (blue), putative 





The TMC024S isolate shows features unique to all the other isolates. In addition to 
the vancomycin-resistance operon that is present in the other isolates (node 13), there 
are two vanW genes (node 646 and node 8870). Unique features of this isolate include 
an isolated VanB-type vanS gene (node 425), an isolated vanX (node 843), and two 
copies of vanB (node 6425, and node 8788). Finally, a vanH gene was present (node 






Figure 11: The C. difficile vancomycin non-susceptible isolate TMC024S 
contains a putative vancomycin resistance operon and additional putative 
vancomycin resistance genes. Gene annotation software and sequence 
examination through NCBI BLAST revealed the location and identity of vancomycin-
resistance elements including: D-alanyl-D-alanine carboxypeptidase (blue), putative 
van ligase (green), vanS (orange), vanR (red), vanW (dark green), and vanZ (pink).  
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To determine how closely related the C. difficile clinical isolates were, a 
sequence alignment was performed between the putative van ligase of the conserved 
operon, which showed a high sequence identity. Percent identity among the samples 
ranged between 99.6% and 100%. CD6, TMC109V and TMC68V1B were most closely 
related followed by TMC024S, and finally, TMC579 and TMC544V2 (Figure 12). The 
phylogenetic tree had a sum branch length of 0.005 with a total of 6 sequences and 







Figure 12: High level of relatedness among putative van ligases found in 
vancomycin non-susceptible C. difficile isolates. The phylogenetic tree was 
created using the neighbor-joining method with a sum branch length of 0.005. Tree is 













 Several vancomycin resistance elements from the isolates were searched 
through the NCBI BlastP database. The putative van ligases from the clinical isolates 
matched most closely with the vanG from other C. difficile strains, followed by vanG 
from other members of the Clostridium genus (Figure 13). These similarities were also 
observed with the putative vanT elements present in each of the six isolates (Figure 
14). Both elements from the VanG operon were not similar to enterococcal vanG and 
vanT elements.  
In TMC024S, the putative vanH element unique to this isolate matched most 
































Figure 13: Putative van ligases matched most closely with the vanG ligases from 
other Clostridium difficile strains. The phylogenetic tree had a branch length of 1.2536 
with a total of 368 positions. VanG ligases from the NCBI database were used from the 
following organisms: Clostridium difficile 1 (WP_021360551.1), Clostridium difficile 2 
(WP_021382963.1), Clostridium sufflavum (WP_110462065.1), Clostridium fimetarium 
(WP_092455360.1), Clostrdium sp. 12(A) (WP_024835184.1), Blautia producta 
(WP_171285627.1), Ruminococcus bromii (WP_015523973.1), Enterococcus faecalis 1 
(WP_063856695.1), and Enterococcus faecalis 2 (ABA71731.1). 
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Figure 14: putative vanT genes matched most closely with Clostridium spp. 
members. The phylogenetic tree had a sum branch length of 1.92778 with a total of 
720 positions in the final dataset. The following vanT sequences from the NCBI 
database were used: Clostridium difficile (WP_009893196.1), Clostridium fimetarium 
(WP_092455364.1), Clostridium sufflavum (WP_110462027.1), Ruminococcus 
bromii (WP_015523975.1), Streptococcus agalactiae (WP_041330235.1), 




















Figure 15: TMC024S putative vanH matched most closely with E. faecium and 
E. faecalis. The phylogenetic tree had a sum branch length of 0.7991 with a total of 
323 positions in the final dataset. The following vanH sequences from the NCBI 
database were used: Enterococcus faecium 1 (WP_063856701.1), Enterococcus 
faecalis 1 (WP_032489745.1), Enterococcus faecalis 2 (WP_172863810.1), 
Enterococcus faecalis 3 (WP_099156040.1), Enterococcus faecium 2 
(WP_127841138.1), Enterococcus faecium 3 (WP_115250287.1), Clostridium 
methoxybenzovorans (WP_024345223.1), Clostridum argentinense 
(WP_039635344.1), Paenibacillus thiaminolyticus (WP_063856708.1), 
Alicyclobacillus shizuokensis (WP_083517214.1). 
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 Sequence analysis suggests vancomycin-resistance elements are 
located on the chromosome 
Several plasmids have been isolated and annotated for C. difficile (Table 3). 
Sequences derived from our plasmid extraction pipeline were searched through the 
NCBI database to determine if they were plasmid or chromosomal DNA for each 
isolate (Table 7-Table 12). TMC024S showed presence of plasmid DNA, but these 
were plasmids that have already been annotated for C. difficile and do not contain 
vancomycin-resistance genes. Conversely, annotation of chromosomal DNA via 
RAST indicated the presence of one vanZ gene on node 7 of TMC68V1B; no other 
vancomycin-associated genes were found with this approach. Attempts to isolate 
plasmid DNA from the isolates were also unsuccessful. Taken together, these data 

























Table 7: CD6 putative plasmid DNA was found to be chromosomal without any 
resistance elements 
Node Length (bp) Chromosome (C) 
or Plasmid (P) 
1 2,334 C 
2 2,140 C 
3 1,579 C 
4 1,219 C 
5 864 C 
6 758 C 
7 586 C 
8 544 C 
 
 
Table 8: TMC109V putative plasmid DNA was found to be chromosomal without 
any resistance elements 
Node Length (bp) Chromosome (C) 
or Plasmid (P) 
1 39,391 C 
2 2,925 C 
3 2,192 C 
4 1,615 C 
5 856 C 
6 749 C 
7 724 C 
8 619 C 
9 575 C 






Table 9: TMC544V2 putative plasmid DNA was found to be chromosomal without 
any resistance elements. 
Node Length (bp) Chromosome (C) 
or Plasmid (P) 
1 99,342 C 
2 94,916 C 
3 72,596 C 
4 2,724 C 
5 2,392 C 
6 1,575 C 
7 1,311 C 
8 1,301 C 
9 885 C 
10 809 C 
11 708 C 
12 669 C 
13 620 C 
14 593 C 
15 541 C 
 
Table 10: Putative plasmid DNA was found to be chromosomal without any 




or Plasmid (P) 
1 99,499 C 
2 97,665 C 
3 94,916 C 
4 72,881 C 
5 2,724 C 
6 2,392 C 
7 1,575 C 
8 1,386 C 
9 809 C 
10 620 C 
11 594 C 
12 541 C 
13 535 C 
14 512 C 




Table 11: Putative plasmid DNA was found to be chromosomal without any 
resistance elements in TMC68V1B. 
Node Length (bp) Chromosome (C) 
or Plasmid (P) 
1 100,904 C 
2 99,462 C 
3 97,425 C 
4 94,916 C 
5 72,596 C 
6 2,724 C 
7 2,392 C 
8 1,575 C 
9 1,028 C 
10 809 C 
11 734 C 
12 620 C 
13 617 C 
14 600 C 
15 597 C 
16 569 C 
17 541 C 
 
Table 12: Putative plasmid DNA mapped to existing C. difficile plasmids, but it 




or Plasmid (P) 
1 44,851 ATCC9689 = DSM 1296 
unnamed plasmid 
2 41,219 C 
3 12,653 plasmid pCD-WTSI2 
4 2,925 C 
5 2,287 C 
6 1,520 C 
7 854 C 
8 821 C 
9 622 C 
10 620 C 
11 575 C 




 Enterococci co-colonization of C. difficile patients 
The prevalence of Enterococcus species in stools of CDI patients from Texas and 
Kenya was determined by plating stools on enterococci-specific media. In adults, 70% 
of the CDI patient stools contained enterococcus, while 50% of stools from children 
had enterococcus. The odds of enterococcus colonization in CDI stools was 3 times 
(95% CI [1.39-5.85]) the odds of C. difficile-only colonization in Kenya children, 5 times 
(95% CI [1.11-22.66]) in Kenyan adults, and 4 times (95% CI [1.39-2.53]) in Texas 
adults with CDI (Figure 16).  
Because of the importance of vancomycin in CDI treatment, the proportion of CDI 
stools containing VRE was determined by culturing stool samples on SBM and 
incubating aerobically for growth (219). VRE was present in 6% of the stools of Kenyan 
children, 27% of Kenyan adults, and 31% of Texas adults with CDI (Figure 17). The 
stools were further examined to determine whether there were vancomycin-resistant 
C. difficile strains colonizing the same patients.  Co-colonization by vancomycin-
resistant isolates of both bacteria occurred in 42% of the Texas patients and 45% of 









Figure 16: Enterococci colonization in CDI stools. Stools were streaked onto 
Slanetz-Bartley Media (SBM) and incubated aerobically at 37 ºC for up to 48 hours. 
Samples were considered presumptively positive for enterococcus if colony growth 
was apparent on the plates. Colonies varied from an opaque, white color to a deep 
maroon color. Colony size also varied. In some cases, multiple colony types were 
present on the plate. Negative results indicated that no colony growth was observed 






































Figure 17: Proportion of vancomycin-resistant enterococci in CDI stools. Stools 
were streaked onto SBM containing 4 µg/ml vancomycin and incubated aerobically at 
37 ºC for up to 48 hours. Samples were considered positive for vancomycin-resistance 
if colony growth was apparent on the plates. Colonies varied from an opaque, white 
color to a deep maroon color. Colony size also varied. In some cases, multiple colony 
types were present on the plate. Negative results indicated that no colony growth was 















































The stools were further examined to determine whether there were 
vancomycin-resistant C. difficile strains colonizing the same patients. Co-colonization 
by vancomycin-resistant isolates of both bacteria occurred in 42% of the Texas 
patients and 45% of Kenyan patients. By comparing frequencies, both Texas (𝜒2 = 
30.6, p < 0.0001, df = 1) and Kenyan adults (𝜒2 = 29.8, p < 0.0001, df = 1) with CDI 
showed a statistically significant correlation between vancomycin-resistant C. difficile 
and VRE in the same stool (Figure 18). These results suggested that both types of 
vancomycin-resistant bacteria are not present together in the same stool by chance. 
 
Figure 18: Association between vancomycin-resistant C. difficile and 
vancomycin-resistant enterococci. Data analysis was performed in RStudio 
(version 1.2.1335) using Pearson’s Chi-Squared Test for Independence with Yate’s 







 Effect of Enterococci on CDI virulence factors 
 
Toxin production and sporulation were examined for isolates grown from stool 
samples to determine if enterococci co-colonization in CDI stools affect C. difficile 
pathogenesis. The results showed that enterococci co-colonization did not impact C. 
difficile toxin production (𝜒2 = 0.18, p = 0.67, df = 1). However, there was a significantly 
higher percentage (45.2%) of spore-producing isolates in C. difficile-only stools versus 
co-colonized stools (𝜒2 = 12.03, p = 0.0005, df = 1) (Figure 19).  The odds of having 
spores in C. difficile-only stools was 3 times higher than the odds of having spores in 






Figure 19: Proportion of spore-producing C. difficile isolates in CDI and co-
colonized stools. There was a significantly higher number of spore-producing 
isolates in the C. difficile-only colonized stool versus the co-colonized stool (𝜒2 = 
































 Effect of Enterococci co-colonization on CDI patients 
A subset of the Kenyan CDI patients whose medical data were available was 
examined to further understand the clinical implication of enterococci co-colonization 
in CDI patients.  In adults, enterococci-C. difficile co-colonization was observed most 
often in the 30-39 age group (45%), followed by 40-49 age group (22.5%), and 50-59 
age group (18.5%). C. difficile-only colonization was most common among the 40-49 
age group. More than 60% of all groups were married, which may have increased risk 
of infection in these patients. A higher percentage of the females (57%) were co-
colonized compared to the males (Table 13, A). For the children, 0-12 month age 
group had the highest percentage of co-colonization (52%). However, 68% of this age 
group were neither infected with C. difficile nor enterococci, suggesting that diarrhea 
in these children was caused by other agents. The 13-24 month age group had the 
next highest percentage (43%) of co-colonization (Table 13, B). 



































Table 13: Characteristics of Kenyan patients with Enterococci and C. difficile co-




Duration of CDI diarrhea was also examined in relation to co-colonization. 
There was a significantly higher number of patients (n = 32) with chronic diarrhea in 
the co-colonized group versus patients that were only colonized with C. difficile (n = 
4) (𝜒2 = 9.62, p = 0.001925, df = 1). The odds of having chronic diarrhea in co-
colonized patients was 5 times higher than that of chronic diarrhea from C. difficile-
only colonization (95% CI = 1.70-15.90). These data suggested that co-colonization 
may play a role in the duration of diarrhea (Figure 20).  
 
 
Figure 20: Effect of enterococci and C. difficile co-colonization on disease 
duration in the Kenyan adult patients. Each group indicates whether patient stool 
contained enterococci only, C. difficile only or co-colonization by both bacteria. These 
groups are broken down further into the number of patients that presented with either 




Antibiotic usage by the patients prior to developing diarrhea was examined, 
since it is a major risk factor for intestinal overgrowth for both C. difficile and 
enterococci. Penicillin was the antibiotic class taken most often by the patients before 
their hospital visit (83.6%), followed my nitroimidazoles (40.8%), macrolide (24.5%), 
fluoroquinolone (24.5%), proton-pump inhibitor (PPI) (24.5%), sulfonamide (22.4%), 
and cephalosporins (20.4%). Fluoroquinolones showed a significant increase in 
percent (16.3%) of patients with chronic CDI symptoms versus acute CDI symptoms 
(𝜒2 = 5.85, p = 0.0155, df = 1). There was no statistically significant difference between 
chronic and acute diarrhea in patients taking the other antibiotics. Together, these 
data suggest that previous broad-spectrum antibiotics use may promote enterococci-





Figure 21: Prior antibiotic use in Kenyan patients co-colonized with enterococci 
and C. difficile. Patient data was analyzed with RStudio (version 1.2.1335) using 
Pearson’s Chi-Squared Test for Independence with Yate’s Continuity Correction (χ2 





 Examining potential transfer of vancomycin-resistance elements from 
enterococci to C. difficile   
 
As vancomycin resistance has not been frequently observed in C. difficile and it is 
not intrinsic to the bacterium, we sought to determine the origin of these resistance 
genes. To that end, we attempted to assess whether there VRE could transfer 
resistance elements to susceptible C. difficile isolates. Initially this was done using 
VRE isolates and susceptible C. difficile isolates from the same stool (Figure 22). No 
transfer was observed over the course of 10 days of co-culture cycles.  
Another approach was taken by utilizing one susceptible C. difficile isolate (CD 
507) and culturing it with various vancomycin-resistant enterococci isolates and 
propagating for a total of 5 days. Again, there was no change in susceptibility of the 
CD507 isolate (Figure 23). These results suggested that transfer may not be occurring 








Figure 22: Continued susceptibility of C. difficile isolates after co-culture with 
vancomycin-resistant enterococcus from the same stool. Susceptible C. difficile 
isolates were co-cultured with VRE taken from the same stool. Various media types 
were used to check for growth and contamination. Samples were propagated for 10 







Figure 23: Continued susceptibility of C. difficile isolates after co-culture with 
vancomycin-resistant enterococcus isolate from a different stool sample. One 
susceptible C. difficile isolate was co-cultured with a VRE from different patient stool. 
Different media types were used to check for growth and contamination. Samples 







 C. difficile genomes reveal vancomycin-resistance elements 
Although de novo sequence assemblies from multiple C. difficile isolates yielded a 
variety of genome and GC contents (Table 4), assembled genomes sizes in this study 
are consistent with published C. difficile genome sizes that range from 4.07 Mbp for 
common C. difficile reference genome 630 (224) to between 4.1 and 4.3 Mbp for other 
strains (217, 225-228). This indicates that our de novo assembly method was valid 
and produced sequences within the normal range of C. difficile genomes.  
Despite the MiSeq analysis having high depth coverage, long read resequencing 
of the isolates may be needed to properly assemble the genomes and to enable us to 
accurately identify components of the vancomycin resistance operons. This can be 
achieved by utilizing PacBio or Oxford Nanopore sequencing platforms to produce 
long reads and using a program such Unicycler to produce a hybrid de novo assembly 
with the current MiSeq data. One advantage to using a hybrid assembly is sequence 
refinement of putative genes and potential variants (229). Duplicated genes and 
tandem repeats are easily recovered from long-read technologies and can help 
determine linage of certain gene regions, especially those involved in antimicrobial 
resistance (230). Additionally, plasmid DNA reconstruction is more reliable when 
supplemented with long-read sequencing (231). Overall, using hybrid assemblies 
would greatly refine vancomycin resistance gene sequences identified and would 
provide a more accurate depiction of the genes present in the vancomycin non-
susceptible C. difficile isolates. 
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The suggested coverage depth for bacterial genomes to ensure adequate single 
nucleotide polymorphisms (SNPs) discovery is 60X (232). Our coverage depths were 
well over double what the literature considers to be adequate for sequencing SNPs.  
Even though the N(50) values give some measure of the average contig length, it 
is difficult to compare this value among the isolates sequenced because they vary in 
length. As expected, the N(75) values are less than the N(50) values but still give a 
good indication of the sequence assemblies. Overall, the high coverage depth and 
N(50) values indicate thorough sequencing experiments for the isolates. In terms of 
the average percent total coverage, the isolates were all close to 93% coverage. 
Depending on the isolate, the values ranged from 90-97% when compared to a single 
isolate.  
Both RAST and Prokka use different algorithms for annotation and thus, the 
consistency between these two annotation methods confirmed presence of 
vancomycin-resistance elements. In evaluating the quality of annotation with RAST, 
various “functional roles” or genes associated with C. difficile were correctly identified 
(Table 6). The coarse consistencies are all relatively high, indicating that annotations 
are self-consistent. The fine consistency, although expected to be lower than the 
coarse consistency, was very low in the case of TMC024S and, to a lesser extent, 
TMC109V. This means that the number of gene instances predicted was lower for 
these samples than the actual number. Given that annotations for regions of interest 
were also checked manually through NCBI BLAST, the chance of incorrect 
annotations was low. Overall, utilizing RAST as a system for gene annotation was 
successful in pinpointing vancomycin-resistance elements in C. difficile isolates.  
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Mapping of the vancomycin resistance genes showed a variety of elements both 
contained as a set of genes and isolated elements. Additionally, all operons in the C. 
difficile isolates were contained between the same two genes: a FAD-dependent 
oxidoreductase upstream of the operon and a TCP38/MEM64 family protein 
downstream (Figure 6-Figure 11). This putative vancomycin resistance operon is 
conserved among our isolates. Examination of the gene order shows a vanT gene, 
indicative of a D-alanine-D-serine type resistance. This arrangement matches the 
VanG operon found in Enterococcus species, however, the C. difficile putative vanG 
operon lacks vanU, vanW, and vanY elements. This suggests that a direct transfer 
was unlikely, and if a transfer did occur, it occurred much earlier in time. The gene 
arrangement seems  widespread in the C. difficile isolates, with about 85% of isolates 
containing vanG-like clusters, but various studies have shown that these genes are 
not functional and do not contribute to significantly to vancomycin resistance (110, 
163, 164). Several VanG arrangements have been described in enterococci and do 
not seem to be well conserved among E. faecium (233, 234). In other Clostridium 
species, the arrangement of vanG-like operons is not well conserved. While the 
arrangement of C. difficile VanG has been described as VanRSGXYT, Clostridium 
acidurici contains VanRWGXYT, and Clostridium argentinense has VanYGTmTr (235). 
Analysis of vanG-like operon arrangements could not be compared for Clostridia 
species most closely related to our isolates, as that information was unavailable. Even 
though there are differences in gene arrangements among Clostridia, the most 
probable evolutionary scenario is an ancient event involving Clostridium species 
members, causing divergence from other Gram-positive anaerobes. 
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Other interesting features include the presence of isolated vanZ and vanW genes 
in the isolates. The vanW gene is reported as a putative hydrolase and has only been 
reported in C. difficile associated within a silent vanB2 operon (236). In all the isolates, 
there were two vanW genes present. One gene is flanked by an 
exonuclease/endonuclease/phosphatase (EEP) family protein and a protein kinase, 
while the other resides between a fis-family transcriptional regulator and a ubiD family 
decarboxylase. One exception is the TMC024S isolate. Because the vanW genes 
were present on shorter contigs, they were not large enough to capture sequences 
flanking vanW and we were unable to confirm if the same trend was seen in this 
isolate. Again, the presence of these genes seems to have been derived from an 
earlier ancestor. The presence of the vanW gene needs to be explored further in terms 
of expression, contribution to vancomycin non-susceptibility, and gene regulation.  
Four orthologs of E. faecium vanZ have been identified in C. difficile and have been 
shown to confer modest teicoplanin resistance despite the lack of an associated VanA 
operon (237). Additionally, it seems expression of vanZ in C. difficile is induced by the 
antimicrobial peptide LL-37 (237). Because vanZ is closely associated with the VanA 
operon (238) many questions arise about how vanZ became isolated in C. difficile. 
Even though it has been shown that this gene does not contribute to vancomycin 
resistance, it is important to understand the origin of this gene to find avenues to test 
other isolated resistance genes. 
Three isolates (TMC68V1B, TMC544V2, and TMC579) contained a vanRS two-
component system without any other vancomycin-resistance genes associated with 
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it. The purpose of these genes remains unclear. A future study could address 
functionality and regulation of these genes.  
TMC024S was unique compared to the other isolates. It contained the van operon, 
but also a VanB-type sensor kinase, and a vanH gene, absent from all the other 
isolates. Since vanH is a feature of the VanA operon, and other resistance types 
producing precursors terminating in D-ala-D-lactate, a thorough investigation needs to 
be conducted to determine its role, if any, in non-susceptibility.  
The presence of a vancomycin-resistance operon in non-susceptible isolates was 
expected, however, the presence of isolated genes from various resistance types was 
not. It is possible that C. difficile-specific recombination systems could have altered 
conjugation or transposition products yielding one or two gene components 
throughout the genome (239). Given that vanZ has been shown to be functional 
independent of an operon, it opens the door to many questions about how the other 
individual genes interact in the C. difficile genome. Perhaps a more likely explanation 
is that the short-read sequencing was not adequate for accurate assembly of the 
genome and may need to be supplemented with long read sequencing data to resolve 
areas where only one or two genes may be present.  
Although it was hypothesized that vancomycin resistance elements may originate 
from Enterococcus spp., phylogenetic analysis of vanG ligases and the vanT 
racemase among Clostridium species, other Gram-positive anaerobes, and 
enterococci showed the putative ligases in the isolates had the highest similarity 
among the Clostridium genus. However, it is important to note that this gene may not 
contribute to vancomycin non-susceptibility in C. difficile (163), so this phylogeny may 
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not be relevant in determining the origin of genes conferring vancomycin resistance. 
In terms of the putative vanH in TMC024S, phylogenetic and multiple sequence 
analyses suggested that this gene originated from enterococci, however, functional 
analysis needs to be performed in order to determine if this gene is contributing to the 
resistance phenotype. 
The two groups of vancomycin resistance elements in the isolates (putative vanG 
operon, and VanB-like elements in TMC024) may follow different evolutionary 
scenarios. It is unlikely that putative vanG genes were transferred from enterococci 
because of a low sequence identity to enterococcal vanG-like elements when 
compared to vanG from other organisms. It is more likely based on the phylogenetic 
analysis that an ancient event occurred diverting Clostridia from other Gram-positive 
anaerobes (Figure 13).  
The putative vanH from TMC024S presents a potential horizontal gene transfer 
event from enterococci given the high sequence similarity and relatedness (Figure 
15). Although this needs to be evaluated more thoroughly, the presence of VanB-like 
elements in C. difficile in one non-susceptible isolate may indicate more than one 
mechanism of vancomycin non-susceptibility. Again, more robust sequencing needs 
to be employed to help resolve areas containing these vancomycin resistance genes, 
as it is unlikely that they are found isolated throughout the genome. This will also 
address the issue of our putative vanH having a partial sequence, which may change 
the hypothesized horizontal gene transfer event. 
 Sequence analysis suggests vancomycin-resistance elements are 
located on the chromosome 
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By subjecting the clinical isolates to the plasmidSPAdes pipeline, putative plasmid 
sequences were extracted from the sequencing data. This program operates under 
the assumption that plasmid DNA is present at a higher copy number than the 
chromosome and should have a higher coverage (205). These sequences all mapped 
to either existing chromosomal or plasmid DNA. The recognition of two known plasmid 
sequences from our sequencing samples validates the use of this program. Analysis 
of the known plasmid sequences indicated an absence of vancomycin-resistance 
elements. With failed attempts at experimentally isolating plasmid DNA from these 
isolates, it is likely that the vancomycin-resistance genes reside on the chromosome.  
 
 Enterococci co-colonization of C. difficile patients 
C. difficile and enterococci occupy the same niche in the human gut. 
Establishment of disease and proliferation of these bacteria is often mediated by 
congruent risk factors. Because of this, we sought to explore the prevalence of 
enterococci and vancomycin-resistant enterococci in CDI stools and describe how 
their presence might affect CDI patients. We analyzed stool samples of patients from 
Kenya and Texas and used patient information for a subset of the Kenyan patients to 
help inform the discussion.  
Our data showed that enterococci colonization varies between the adult and 
children populations. In terms of enterococci colonization in children, our results 
showed a higher colonization rate than in the literature. Although enterococci are 
normal gut commensals, antibiotic usage can increase colonization of Enterococci 
spp. in infant stools (127, 240), one explanation for the increase. There may be other 
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factors that caused diarrheal symptoms favorable for enterococcal colonization. Not 
many studies have been done looking at enterococci colonization in children as VRE 
colonization studies are more relevant in the health landscape at present. Because of 
this, it is difficult to gauge what is considered higher than normal. Given that gut 
microbiota changes occur rapidly in the children (240), colonization information may 
be based on a variety of factors not explored in this study.  
Our results indicated a  high level of C. difficile-vancomycin-resistant 
enterococci co-colonization among adult patients, which is a little lower than the rates 
reported by others (145). One reason for the discrepancy between the Fujitani, et. Al 
study and others would be that only  toxin-positive C. difficile stools were screened for 
VRE presence and other studies taking a more unbiased approach have shown that 
C. difficile toxin-positive stools were highly correlated with VRE colonization (119, 
140). Kenyan patients may have been treating their diarrhea with antibiotics without 
the guidance of a medical professional. The use of one or more antibiotics could have 
exacerbated overgrowth conditions, allowing for an increase in transfer of resistance 
elements between Enterococci spp. Despite the Texan patients having regulated 
antibiotic use, the proportions of co-colonization were still very high, indicating that 
over time, VRE may be more prevalent among CDI patient populations around the 
world. The increase in VRE colonization in CDI patients could increase the risk of a 
secondary VRE infection as seen with other patient types. For example, in patients 
with cancer, although only a small percentage may be colonized with VRE (~6%), 60% 




 Effects of enterococci on CDI virulence factors 
Our data showed a significantly high proportion of C. difficile non-susceptibility 
to vancomycin in stools containing VRE in both Texas and Kenya, describing a 
possible reservoir of vancomycin-resistance elements. Since the shift to vancomycin 
as the recommended treatment for CDI (36, 37, 46, 47), increased use of vancomycin 
may select for C. difficile isolates containing vancomycin resistance elements. 
Coupled with the fact that enterococci and C. difficile can occupy the same niche 
during CDI, a perfect storm may be created for emergence of vancomycin non-
susceptible C. difficile. There has been evidence of genetic transfer of other antibiotic 
resistance elements to C. difficile (149, 242), so it may be possible in this case as well. 
Genetic analysis through next generation sequencing (NGS) would allow further 
insight into the origin of these elements. 
Several studies indicated that individuals with toxin-producing C. difficile strains 
also showed a higher level of enterococcal colonization, however, this was not the 
case in the present study. Possibly, compensatory virulence factors might prevail in 
this cohort of isolates or some other epidemiological factors could be at play. 
Interestingly, spore-producing C. difficile isolates were significantly more present in 
co-colonized stools versus singly colonized stools; to our knowledge, this is a result 
not yet reported in the literature. The selection of spore-producing isolates in the 
presence of enterococcal colonization might indicate competition between the two 
bacteria and lead to persistence of CDI symptoms as spore-producing isolates are 




 Effects on enterococci co-colonization on CDI patients 
In terms of CDI disease presentation with enterococcal co-colonization, CDI 
symptoms appear to be prolonged, with patients experiencing diarrhea for over 2 
weeks. As previously stated, this could be due the inability for normal gut microbiota 
from reestablishing itself. Additionally, fluoroquinolone use prior to a CDI diagnosis 
also correlates with a longer duration of the diarrheal symptoms. As a risk-factor 
antibiotic for both enterococci and C. difficile overgrowth in the gut, prolonged or 
improper use of this broad-spectrum antibiotic prevents recolonization of normal gut 
flora and potentially drives acquisition of antibiotic resistance elements.  
Taken together, the data leads us to hypothesize the following model for the 
role of vancomycin-resistant enterococcal colonization during a C. difficile infection. 
During CDI, co-colonization may lead to chronic diarrhea. Prior antibiotic use by 
patients can promote C. difficile overgrowth in the gut followed by CDI disease 
presentation. Loss of colonization resistance can also allow enterococcus overgrowth. 
Presentation of CDI symptoms is combated with vancomycin treatment, allowing VRE 
to persist, preventing normal flora from re-establishing in the gut. Continued 
vancomycin treatment will also impede recolonization by normal flora. Spore-
producing C. difficile isolates may germinate, and reestablish a CDI without normal 
flora, necessitating more treatment. This perpetuates a cycle in which vancomycin is 
readily used and selects for VRE, allowing for a gut landscape that may promote 
recurrence and horizontal gene transfer of vancomycin-resistance elements from 
enterococcus to C. difficile. 
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This model would be enhanced by knowledge of recurrence rates of CDI in 
patients co-colonized with enterococci, however, given our present dataset, this was 
not possible to examine, nor has this been explored in the literature to our knowledge. 
Sequencing data of the vancomycin non-susceptible C. difficile isolates may reveal if 
resistance elements have been transferred from enterococci. The present study 
demonstrates that co-colonization of CDI patients by enterococci may impact duration 
of CDI symptoms, and presence of VRE may drive vancomycin non-susceptibility in 
C. difficile. Our data highlight the importance of further study examining VRE co-
colonization in CDI patients.  
 
 Transfer of vancomycin-resistance elements 
The co-culture propagation experiments to explore potential transfer of resistance 
elements via conjugation were unsuccessful, however, there are other factors to 
explore before concluding that transfer of vancomycin-resistance elements does not 
happen between enterococci and C. difficile. Additionally, lack of transfer with this 
experiment does not preclude transfer by transformation, a low frequency event. 
 One thing to be considered is the strain of C. difficile isolate used. In our 
experiment, the strain of clinical isolate was unknown. Although laboratory C. difficile 
strains (i.e. CD630) show a high conjugation efficiency, ribotype 027 strains R20291 
of C. difficile, which are becoming more endemic in the clinical setting, have low 
conjugation frequencies (244). Since our isolates are from a clinical setting, this may 
be a factor in the failure of the experiment. Designing experiments that increase 
conjugation frequency between the bacteria might help answer the question of 
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transference. For example, a filter mating technique or direct plating method might 
have a better chance of yielding transconjugants.  
 
 Future Directions 
Due to laboratory closures as a result of the COVID-19 pandemic, the experiments 
suggested below could not be fully explored but still present avenues for furthering 
this work. As mentioned previously, supplementing current MiSeq data with data from 
long-read sequencing technologies would result in more refined assemblies and will 
allow us to conclusively determine the arrangement of the vancomycin-resistance 
genes in the vancomycin non-susceptible C. difficile isolates. Additionally, functional 
studies of the genes found would be a logical next step, including qRT-PCR to 
measure expression, gene knockouts, and HPLC analysis of the peptidoglycan 
precursors. Assays determining racemase activity for vanT and dipeptidase activity 
for vanXY can be used to describe the functionality of these genes. 
One avenue to pursue moving forward would be to classify this phenotype based 
on the ribotypes of the isolates. If the non-susceptibility phenotype is isolated to one 
or a few ribotypes, then this may help inform intervention strategies to limit spread of 
the resistance genes. 
In terms of epidemiology, the impact of vancomycin non-susceptibility needs to be 
described in terms of disease severity, patient outcomes, and recurrence rates. A 
comprehensive examination of the relationship between enterococci and C. difficile is 
necessary and may be important in understanding how C. difficile pathogenesis may 
be impacted by other co-inhabiting gut bacteria. Assessing patient outcomes and 
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recurrence rates in CDI patients co-colonized by enterococci would help define this 
relationship further.  
Finally, presence of the putative vanH and other putative VanB-like elements in 
TMC024S share a high sequence identity with enterococcal orthologs, suggesting that 
these may have transferred from Enterococcus species members. Although 
functionality of these genes needs to be assessed, it could indicate potential transfer 
of vancomycin-resistance elements. Although our transfer experiments assessing 
conjugative transfer were initially unsuccessful, experiments testing for transformation 
could be pursued before searching for other sources of vancomycin resistance 
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6. Appendix A: Supplementary data  
 
 
Table 14: Quality of assembly based on WGS of CD6. 
Contig Length (bp) Coverage Contig Length (bp) Coverage 
1 1,098,818 149.7 22 2,162 348.7 
2 562,155 322.7 23 1,575 3323.3 
3 429,529 316.0 24 1,346 467.5 
4 402,523 272.3 25 991 2857.8 
5 232,236 371.9 26 775 226.6 
6 218,146 350.6 27 748 531.4 
7 205,873 295.5 28 695 536.7 
8 194,189 297.3 29 603 207.1 
9 149,209 358.4 30 586 199.3 
10 135,492 353.3 35 525 195.6 
11 131,570 335.8 43 469 244.7 
12 72,023 359.0 47 421 317.2 
13 66,850 336.9 48 400 262.4 
14 65,629 322.2 49 396 168.5 
15 19,330 363.7 50 369 148.2 
16 19,228 255.7 51 354 172.0 
17 17,186 285.2 52 334 508.3 
18 1,0322 250.2 53 326 53.5 
19 9,448 346.9 54 326 138.0 
20 6,329 534.7 55 304 195.6 
21 5,608 350.4 





Table 15: Quality of assembly based on WGS of TMC109V. 
Contig Length (bp) Coverage Contig Length (bp) Coverage 
1 485,739 286.9 32 5,528 354.9 
2 484,738 298.8 33 5,508 344.0 
3 455,713 257.2 34 5,225 367.9 
4 334,028 324.4 35 4,807 355.7 
5 278,293 361.8 36 1,849 655.9 
6 162,289 316.3 37 1,849 319.1 
7 159,031 259.4 38 1,738 5.3 
8 154,893 378.1 40 1,387 5582.8 
9 154,299 259.1 44 1,014 5719.8 
10 149,805 362.0 58 798 450.8 
11 147,450 299.7 71 724 2863.9 
12 133,781 383.5 86 706 3828.0 
13 104,664 362.1 107 678 5191.7 
14 90,433 418.0 143 619 4189.2 
15 85,967 330.5 167 597 228.0 
16 80,672 330.8 199 562 5.1 
17 76,796 337.2 261 524 643.7 
18 72,456 366.5 275 520 547.9 
19 70,029 351.8 352 476 632.0 
20 69,743 344.6 425 452 5.2 
21 56,992 318.6 465 439 259.1 
22 56,132 382.5 528 421 6.8 
23 50,821 333.9 538 419 267.6 
24 50,202 313.0 557 415 968.5 
25 24,380 377.8 618 404 96.1 
26 16,320 285.1 624 402 2575.4 
27 12,991 314.3 684 391 397.8 
28 12,590 278.6 698 388 90.4 
29 9,524 335.3 946 351 692.5 
30 9,347 328.6 1016 343 5.2 





Table 16: Quality of assembly based on WGS of TMC544V2. 
Contig Length (bp) Coverage Contig Length (bp) Coverage 
1 353,731 228.5 31 37,854 351.1 
2 309,547 234.3 32 37,554 336.6 
3 289,219 257.9 33 37,241 375.0 
4 244,235 358.9 34 28,609 339.1 
5 238,516 358.0 35 20,519 286.8 
6 236,317 261.6 36 19,013 280.4 
7 149,037 249.2 37 14,688 317.1 
8 146,591 302.1 38 12,500 312.8 
9 140,966 292.3 39 9,342 348.5 
10 128,965 285.0 40 9,186 307.4 
11 114,619 284.5 41 7,575 292.7 
12 113,855 308.8 42 6,192 276.2 
13 112,933 252.1 43 5,580 329.6 
14 97,470 245.4 44 5,508 328.8 
15 96,934 332.0 45 3,766 373.6 
16 96,704 374.1 46 2,948 307.5 
17 94,387 397.7 47 2,804 5496.9 
18 89,241 300.9 48 1,327 452.9 
19 81,329 280.1 49 1,326 5131.0 
20 81,312 276.2 50 1,119 834.6 
21 80,487 292.0 51 1,094 710.5 
22 77,159 306.6 53 994 462.7 
23 73,496 317.9 54 850 662.5 
24 72,395 380.3 67 520 463.7 
25 67,284 344.1 117 420 1652.9 
26 54,852 428.9 137 389 213.7 
27 53,301 292.9 178 374 568.4 
28 52,997 323.3 180 367 377.3 
29 39,077 518.1 203 330 106.6 






Table 17: Quality of assembly based on WGS of TMC579. 
Contig Length (bp) Coverage Contig Length (bp) Coverage 
1 453,118 264.1 36 14,688 370.2 
2 309,242 246.9 37 12,500 338.2 
3 289,170 277.2 38 9,342 391.2 
4 238,550 380.1 39 9,237 349.1 
5 236,307 282.8 40 9,186 349.6 
6 226,775 376.8 41 7,575 324.1 
7 149,037 264.2 42 6,182 315.4 
8 146,718 333.2 43 5,580 358.6 
9 140,966 320.9 44 5,508 369.4 
10 129,000 308.6 45 4,226 661.4 
11 114,619 302.6 46 3,766 402.1 
12 11,3855 330.3 47 3,520 286.7 
13 112,933 270.8 48 2,948 353.3 
14 96,891 362.9 49 2,846 6.7 
15 96,704 410.5 50 2,804 5314.4 
16 94,387 419.9 51 1,659 6.8 
17 89,241 335.6 52 1,653 7.7 
18 81,329 303.3 53 1,620 5.7 
19 81,312 301.5 54 1,327 499.6 
20 80,487 323.8 55 1,326 4932.5 
21 77,157 335.1 56 1,119 882.4 
22 73,478 341.9 57 1,094 759.2 
23 72,395 425.7 59 996 5.6 
24 67,306 372.6 63 850 735.2 
25 54,852 441.3 128 544 264.7 
26 53,301 314.3 203 457 70.6 
27 43,792 359.0 245 421 5.3 
28 38,084 328.4 246 420 1601.2 
29 37,854 382.2 371 403 270.6 
30 37,554 364.8 424 371 680.2 
31 37,241 414.1 433 348 381.6 
32 28,609 365.1 440 345 35.7 
33 20,519 307.7 490 330 116.7 
34 16,115 353.3 553 317 5.2 





Table 18: Quality of assembly based on WGS of TMC68V1B. 
Contig Length (bp) Coverage Contig Length (bp) Coverage 
1 353,620 211.3 30 53,301 297.3 
2 309,831 219.1 31 38,084 302.2 
3 289,166 247.6 32 37,854 360.6 
4 236,317 257.7 33 37,630 343.1 
5 223,089 372.4 34 37,241 395.5 
6 174,487 355.2 35 28,609 340.5 
7 168,849 309.9 36 20,519 292.8 
8 149,038 238.0 37 14,165 321.1 
9 146,588 313.5 38 10,386 313.3 
10 128,719 272.8 39 9,342 368.7 
11 122,927 249.6 40 9,186 315.8 
12 114,128 278.9 41 6,182 291.0 
13 113,855 312.3 42 5,580 325.8 
14 97,519 224.0 43 5,508 346.3 
15 96,704 397.2 44 3,766 394.8 
16 96,531 308.1 45 2,804 5603.3 
17 94,387 413.1 46 1,327 420.3 
18 89,591 361.4 47 1,326 5247.5 
19 81,329 279.7 48 1,119 806.8 
20 81,255 272.4 49 1,094 757.5 
21 80,487 307.3 50 850 714.0 
22 77,172 309.1 51 796 409.2 
23 73,477 322.2 58 562 291.0 
24 72,395 406.3 60 420 1729.5 
25 67,284 351.2 61 419 427.4 
26 65,334 332.0 62 389 280.8 
27 60,187 443.3 67 375 689.4 
28 56,200 376.8 70 348 326.2 





Table 19: Quality of assembly based on WGS of TMC024S. 
Contig Length 
(bp) 
Coverage Contig Length 
(bp) 
Coverage Contig Length 
(bp) 
Coverage 
1 748,144 263.8 46 3,125 11.6 1226 605 5.5 
2 426,285 252.3 47 3,095 10.0 1266 599 6.0 
3 308,401 293.5 48 3,055 735.8 1307 593 8.8 
4 240,806 319.8 49 3,012 288.3 1326 591 5.1 
5 233,400 261.1 50 3,001 6.1 1371 582 5.7 
6 233,385 316.8 51 2,875 12.0 1377 581 5.7 
7 217,554 287.1 52 2,537 15.1 1425 573 5.8 
8 163,878 252.5 53 2,503 7.8 1716 534 5.3 
9 149,115 331.6 55 2,267 5.3 1732 534 5.3 
10 135,414 328.2 57 2,217 280.3 1826 520 429.3 
11 123,766 247.5 58 2,183 9.9 2230 480 5.0 
12 106,102 246.3 63 2,102 5.0 2268 477 112.8 
13 904,063 341.6 64 2,044 6.6 2269 477 6.9 
14 85,764 286.5 65 2,022 5.9 2281 476 427.9 
15 80,836 293.7 66 1,951 8.9 2497 460 462.5 
16 79,533 312.9 70 1,881 5.5 2535 458 5.2 
17 76,485 273.7 71 1,829 5.9 2613 452 5.6 
18 76,002 293.5 82 1,578 5.9 2707 445 5.4 
19 68,253 313.5 86 1,527 4585.4 2742 443 5.1 
20 57,535 286.5 95 1,429 5.0 2777 440 5.9 
21 49,278 303.0 100 1,387 4555.1 2848 435 5.2 
22 41,823 522.0 102 1,380 11.3 2898 431 551.5 
23 40,691 662.3 120 1,292 5.3 3016 424 5.7 
24 39,075 300.7 142 1,173 5.5 3076 420 5.0 
25 38,229 285.3 179 1,079 5.3 3336 405 145.5 
26 35,619 241.7 226 1,014 4607.5 3414 400 321.8 
27 35,533 272.0 243 994 407.4 3520 393 6.5 
28 30,291 276.2 247 989 5.6 3537 392 656.0 
29 29,706 324.2 287 955 5.2 3829 377 5.2 
30 21,970 282.3 395 867 5.0 4099 363 95.7 
31 13,084 264.8 397 865 5.2 4191 359 1458.1 
32 12,603 2444.6 432 840 5.0 4192 359 6.3 
33 12,120 287.1 490 807 5.2 4193 359 5.0 
34 10,223 282.9 492 806 6.0 4227 357 5.0 
35 10,216 261.1 607 758 4195.6 4322 352 5.5 
36 9,358 310.6 722 719 5.0 4580 339 5.3 
37 6,740 1646.9 729 717 6.3 4596 338 1155.0 









































39 5,507 312.0 810 695 1328.5 4830 328 6.9 
40 5,407 288.2 913 664 204.2 4934 324 388.4 
41 4,674 311.5 935 658 5.2 4982 345 1484.8 
42 4,314 258.8 962 652 5.5 5007 321 5.6 
43 3,974 12.0 978 648 480.9 5375 358 522.1 
44 3,349 547.5 1225 605 6.0 5550 301 136.1 
45 3,149 360.7    
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